There are important differences between the 2012 10K and the recent 10K.
First, the company is 4 years older, and has still failed to get even IND approval for a single candidate.
Second, the 2012 10K reported an accumulated deficit of $22,894,827. The recent 10K reports $64,824,201. That's 3X more money spent, with still not a single IND-approved candidate.
Third, the 2012 10K has this optimistic statement regarding its ability to raise capital:
p. F-18 "The Company continues to successfully raise additional capital"
In the recent 10K, the company makes no such claim. All they say is "We may issue additional equity shares to fund the Company’s operational requirements, which would dilute share ownership."
That's a big duhhhh.
Every biotech who fails to get a candidate into clinical trials after this amount of money and time fails. There's no reason to believe that NNVC will be the exception.
News 
Market Data 
Discover 
